Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. is offering up to $4,339,697 of Ordinary Shares in an at‑the‑market offering under a Sales Agreement with A.G.P./Alliance Global Partners dated May 12, 2026. Sales may occur from time to time on Nasdaq or by other lawful methods. A.G.P. will act as sales agent or principal for sales and will receive a fixed commission of 3.0% of gross sales; there is no escrow arrangement. The company reported 81,237,799 Ordinary Shares outstanding as of May 8, 2026. The prospectus supplement notes a March 2026 registered direct offering that sold 8,000,000 Ordinary Shares at $0.50 per share and generated gross proceeds of approximately $4.0 million, together with Series B and Series C warrants exercisable at $0.55. The net proceeds from this ATM program are intended for working capital and general corporate purposes.
IceCure Medical Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners that allows the company to sell ordinary shares from time to time in an at-the-market offering under its existing Form F-3 shelf registration. The company is not required to sell any shares and will direct the timing, price and size of any sales.
A.G.P. will act as sales agent and use commercially reasonable efforts to place shares, earning a 3.0% commission on aggregate gross proceeds from each sale. IceCure plans to use any net proceeds for working capital and general corporate purposes. The agreement includes customary conditions, indemnification, expense reimbursement and a supporting legal opinion on the validity of the shares.
IceCure Medical reported first quarter 2026 results showing continued revenue growth but ongoing losses as it invests in commercialization. Revenue for the three months ended March 31, 2026 rose to $911,000 from $725,000 a year earlier, driven by higher ProSense® sales in the U.S., Canada and Mexico.
Gross profit increased to $295,000 with gross margin improving to 32% from 30%. Operating expenses grew to $4.5 million, mainly from higher research and development and general and administrative costs, while sales and marketing expenses declined. Net loss widened to $4.3 million, or $0.06 per share, similar on a per-share basis to the prior year.
Cash and cash equivalents were $8.1 million as of March 31, 2026, down from $8.9 million as of December 31, 2025, after funding operating activities and capital spending, partially offset by proceeds from share and warrant issuance.
IceCure Medical Ltd. held a Special General Meeting of Shareholders on May 11, 2026. The meeting was initially adjourned at 5:00 p.m. Israel time because there was no quorum, but it reconvened at 6:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders voted on and approved the single agenda item described in the company’s proxy statement filed on April 22, 2026. This report is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8.
IceCure Medical Ltd. has called a Special General Meeting of shareholders for May 11, 2026, to vote on authorizing a potential reverse split of its issued and outstanding ordinary shares at a ratio between 10:1 and 30:1. The Board would have discretion to decide whether to implement the reverse split, the exact ratio within that range, and the effective date. The company states that the goal is to support continued Nasdaq listing, including compliance with the $1.00 minimum bid price requirement, and to potentially make the shares more attractive to a broader investor base. The reverse split would not change the authorized share capital of 2,500,000,000 ordinary shares and is intended to affect all shareholders uniformly.
IceCure Medical expects U.S. revenue from its ProSense® cryoablation systems and cryoprobes to grow more than 30% in the first quarter of 2026 versus the same quarter of 2025, based on preliminary, unaudited estimates. Management links this to adoption following FDA clearance in October 2025 for treating low-risk breast cancer in women aged 70 and above.
The company highlighted strong physician interest at the Society of Breast Imaging 2026 Symposium, where it exhibited ProSense® and supported hands-on training. An award-winning Massachusetts General Hospital cost analysis suggested cryoablation using ProSense® may cut total treatment costs by more than 50% compared to breast-conserving surgery. IceCure plans to report full first-quarter 2026 results on May 14, 2026.
IceCure Medical Ltd. is registering up to 16,000,000 Ordinary Shares for resale by selling shareholders, consisting of up to 8,000,000 shares issuable upon exercise of Series B warrants and up to 8,000,000 shares issuable upon exercise of Series C warrants. No Ordinary Shares are being sold by the company in this registration; the company will receive cash only if the Warrants are exercised. As of March 31, 2026, 81,180,045 Ordinary Shares were issued and outstanding.
The company is offering 8,000,000 Ordinary Shares in a registered direct offering at a combined purchase price of $0.50 per Ordinary Share together with privately placed Series B and Series C warrants.
The offering includes a concurrent private placement of up to 16,000,000 Warrants (8,000,000 Series B Warrants and 8,000,000 Series C Warrants) exercisable at $0.55 per share. Net proceeds are estimated at approximately $3.5 million, intended for working capital and general corporate purposes.